Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Narcolepsy01:07

Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
Fatigue01:21

Fatigue

Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B.

International journal of molecular sciences·2026
Same author

The Global Epilepsy Needs Study (GENS): A mixed-methods, multi-country exploration of the unmet psychosocial and everyday needs of people with epilepsy.

Epilepsia open·2026
Same author

Experiences of women of childbearing age with epilepsy throughout their motherhood journey: Results from a social media listening study.

Epilepsy & behavior : E&B·2025
Same author

Glucocerebrosidase Target Engagement and Therapeutic Plasma and Cerebrospinal Fluid Levels After GT-02287 Administration in Healthy Volunteers.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Survey assessing the reproductive healthcare and information needs of women in Europe of childbearing age living with epilepsy.

Epilepsy & behavior : E&B·2025
Same author

A novel allosteric GCase modulator prevents Tau accumulation in GBA1<sup>WT</sup> and GBA1<sup>L444P/L444P</sup> cellular models.

Scientific reports·2025

Related Experiment Video

Updated: Jun 19, 2026

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

Modafinil for Parkinson's disease fatigue.

Hilary L Tyne1, Joanne Taylor, Gus A Baker

  • 1Department of Neurological Sciences, University of Liverpool, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, L9 7LJ, UK. htyne@ukonline.co.uk

Journal of Neurology
|October 21, 2009
PubMed
Summary

Modafinil may help Parkinson's disease fatigue, showing patient-rated improvement and better sleepiness scores. However, larger trials are needed to confirm efficacy for this common non-motor symptom.

Related Experiment Videos

Last Updated: Jun 19, 2026

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Fatigue affects up to 42% of Parkinson's disease (PD) patients.
  • No established treatments exist for PD-related fatigue.
  • Non-motor symptoms like fatigue present recruitment challenges for clinical trials.

Purpose of the Study:

  • To investigate the efficacy and safety of modafinil for treating fatigue in Parkinson's disease patients.
  • To assess modafinil's impact on fatigue severity, sleepiness, and mood.

Main Methods:

  • A study involving idiopathic PD patients recruited from a Movement Disorders clinic.
  • Exclusion of patients with depression, dementia, or other fatigue causes.
  • Assessment using Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), Epworth Sleepiness Scale (ESS), and UPDRS, with modafinil titrated up to 400 mg/day.

Main Results:

  • No significant changes in safety measures or FSS scores were observed.
  • Patients reported subjective improvement in fatigue when treated with modafinil compared to placebo.
  • A statistically significant improvement in Epworth Sleepiness Scale (ESS) scores was noted (p < 0.05).

Conclusions:

  • Modafinil shows a potential benefit for Parkinson's disease fatigue, particularly in subjective ratings and sleepiness.
  • The study suggests modafinil may be a viable option, but larger trials are necessary for confirmation.
  • Significant improvement in Excessive Daytime Sleepiness (EDS) was observed.